放射性^(125)I粒子肿瘤组织间植入联合NP方案化疗治疗非小细胞肺癌的效果比较

^(125)I radioactive particle tumor embedding combined with NP chemotherapy for lung squamous carcinoma and adenocarcinoma

目的对比放射性^(125)I粒子肿瘤组织间植入联合NP(长春瑞滨+顺铂)方案通过锁骨下静脉化疗治疗肺腺癌及肺鳞状细胞癌的效果。方法选择错过手术机会及不愿接受手术治疗的非小细胞肺癌患者60例,根据细胞类型分为A、B两组,A组为腺癌患者26例,B组为鳞状细胞癌患者34例,两组患者瘤体内均在CT引导下植入放射性^(125)I粒子,植入5 d后均行NP方案化疗。放射性^(125)I粒子植入后3个月,亦就是NP方案化疗3个疗程后,对A、B两组患者进行近期疗效和不良反应的评价。结果 60例患者全部可评价疗效,两组差异无统计学意义。结论放射性^(125)I粒子肿瘤组织间植入联合NP方案通过锁骨下静脉化疗治疗非小细胞肺癌,创伤小,操作简便,近期疗效显著,对肺腺癌和肺鳞状细胞癌的疗效无明显差异,是一种安全可行的有效方法。

Objective To compare the effect of the ^125I radioactive particle tumor embedding combined with NP chemotherapy via subclavian vein for hmg squamous carcinoma and adenocarcinoma. Methods 60 lung cancer patients that with advanced stage or refused to accept operation were enrolled this study. For the pathologic characteristics, there were 26 cases with adenocarcinoma and 34 with squamous carcinoma. All the patients received 3 cycles of NP chemotherapy via subclavian vein five days after ^125I radioactive particle tumor embedding, and evaluate the therapeutic effect of them. Results All the 60 patients could be assessed, and the therapeutics effect between the pulmonary squamous carcinoma and adenocarcinoma was not significant （ P 〉 0. 05）. Conclusion ^125I radioactive particle tumor embedding combined with NP chemotherapy for lung squamous carcinoma and adenocarcinoma is safe, reliable, minimal invasive, easy to manipulate, and has similar initial therapeutics effect.